Soligenix announces publication demonstrating successful formulation and heat stabilization of filovirus vaccine platform for ebola and marburg virus diseases

Princeton, n.j., aug. 23, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the formulation of single-vial platform presentations of monovalent (single antigen), bivalent (two antigens) and trivalent (three antigens) combinations of filovirus vaccine candidates.
SNGX Ratings Summary
SNGX Quant Ranking